Table 1.
Patients' characteristics of 341 patients treated with EGFR-TKIs
| Characteristics | No. of patients | % patients |
|---|---|---|
| Total | 341 | 100 |
| Age (years) | ||
| Mean (± SEM) | 65.2(± 0.6) | |
| < 60 | 102 | 29.9 |
| ≥ 60 | 239 | 70.1 |
| Sex | ||
| Female | 167 | 49.0 |
| Male | 174 | 51.0 |
| Histologic type | ||
| Adenocarcinoma | 296 | 86.8 |
| Squamous cell carcinoma | 34 | 10.0 |
| Others | 11 | 3.2 |
| Smoking history | ||
| Current | 60 | 17.6 |
| Former | 110 | 32.3 |
| Never | 171 | 50.1 |
| Disease stage | ||
| IV | 206 | 60.4 |
| IIIB | 54 | 15.8 |
| I-IIIA | 18 | 5.3 |
| Recurrence after surgery | 63 | 18.5 |
| Performance status | ||
| ≥ 2 | 141 | 41.3 |
| 0-1 | 200 | 58.7 |
| No. of prior chemotherapy regimens | ||
| ≥ 2 | 118 | 34.6 |
| 0-1 | 223 | 65.4 |
| Prior thoracic radiotherapy | ||
| Yes | 47 | 13.8 |
| No | 294 | 86.2 |
| Preexisting pulmonary fibrosis | ||
| Yes | 48 | 14.1 |
| No | 293 | 85.9 |
| Preexisting pulmonary emphysema | ||
| Yes | 82 | 24.0 |
| No | 259 | 76.0 |
| EGFR mutation status | ||
| Wild type | 57 | 16.7 |
| Mutant | 91 | 26.4 |
| Not evaluated | 193 | 56.9 |
| Types of EGFR-TKI | ||
| Gefitinib | 302 | 88.6 |
| Erlotinib | 39 | 11.4 |